Comparison of Efficacy and Safety of Fondaparinux and FraxiParine in Patients with Unstable Angina or Myocardial Infarction without ST-segment Elevation in China.

Trial Profile

Comparison of Efficacy and Safety of Fondaparinux and FraxiParine in Patients with Unstable Angina or Myocardial Infarction without ST-segment Elevation in China.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Fondaparinux sodium; Nadroparin calcium
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Actual end date 30 Apr 2010 added as reported by Chinese Clinical Trial Register.
    • 01 Mar 2011 Status changed from recruiting to competed, as reported in the Chinese Medial Journal.
    • 01 Mar 2011 Primary endpoint 'Myocardial-infarction-event-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top